Sharon Thompson
Family · Philadelphia, PANPI 1184191108
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,328, 4.8 times the $692 reported in 2021. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $101.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$854
- Alnylam Pharmaceuticals Inc.$625
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$501
- AbbVie$475
- GSK$404
- plus $5K from 32 others
What the payments were for
- Food & beverage$9,336100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $1,071 |
| AstraZeneca | 8 | $854 |
| Alnylam Pharmaceuticals Inc. | 6 | $625 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $501 |
| AbbVie | 5 | $475 |
| GSK | 4 | $404 |
| Teva Pharmaceuticals USA, Inc. | 4 | $370 |
| Gilead | 3 | $345 |
| Phathom Pharmaceuticals, Inc. | 4 | $327 |
| Heartflow, Inc. | 2 | $304 |
| Inspire Medical Systems, Inc. | 3 | $294 |
| Otsuka America Pharmaceutical, Inc. | 2 | $235 |
| Neurocrine Biosciences, Inc. | 3 | $231 |
| Idorsia Pharmaceuticals US Inc | 3 | $225 |
| Pfizer | 2 | $217 |
| Johnson & Johnson | 2 | $205 |
| Regeneron Healthcare Solutions, Inc. | 2 | $197 |
| Sanofi | 1 | $185 |
| Biogen | 3 | $177 |
| Abbott | 2 | $172 |
| Cipher Pharmaceuticals US LLC | 1 | $154 |
| CSL Behring | 1 | $124 |
| Coloplast | 1 | $119 |
| Urovant Sciences Inc | 1 | $119 |
| Astellas Pharma US Inc | 1 | $118 |
| Merck | 1 | $115 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $115 |
| Boehringer Ingelheim | 1 | $113 |
| Amarin Pharma, Inc. | 1 | $108 |
| Esperion Therapeutics, Inc. | 1 | $106 |
| Amgen | 1 | $102 |
| Neurelis, Inc. | 1 | $101 |
| Haemonetics Corporation | 1 | $100 |
| Mylan Specialty L.p. | 1 | $90 |
| E.r. Squibb & Sons, L.L.C. | 1 | $88 |
| Kyowa Kirin, Inc. | 1 | $87 |
| Genentech USA, Inc. | 1 | $86 |
| Insmed, Inc. | 1 | $76 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,336 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Philadelphia
- Bethany ThomasPhiladelphia$126K
- Anne CalvaresiPhiladelphia$81K
- Bethany MooneyPhiladelphia$73K
- Susan Estrella-EadesPhiladelphia$61K
- Michelle Vega-OlivoPhiladelphia$55K
- Danielle LandPhiladelphia$48K
- Nicole SmithPhiladelphia$37K
- Dana SerafinPhiladelphia$31K
- Tammaris KaschakPhiladelphia$27K
- Laura NoltePhiladelphia$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.